Oncimmune Appoints Lung Cancer KOL As Chief Medical Officer
This article was originally published in Clinica
Dr James Jett is to join Oncimmune, a company that has developed an early-stage lung cancer test, as chief medical officer on Jan 1. He is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the US; he has been the principal investigator on the National Jewish Health study on Oncimmune’s blood-based autoantibody assay for early-stage lung cancer, Early CDT-Lung. In his role at the company, Jett will be responsible for overseeing all the R&D activities, as the firm continues to expand commercialization EarlyCDT-Lung. Oncimmune toldClinica earlier this year that it was ramping up US sales of the test. The firm is also developing tests for liver and ovarian cancers.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.